Evolving Clinical Paradigms for LDL Lowering-Focus on Efficacy, Implications, Side Effects, and Safety Results of Clinical Trials Evaluating PCSK9 Inhibition, APOB Suppression, and Other Novel Targets for Primary and Familial Hyperlipidemia-James M. McKenney, PharmD